Topic Archives: Eisai (ESALY)

I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]

Here’s the lead-in to the ad that caught our readers’ attention this week: “This ‘Perfect Storm’ Stock Is Set to Deliver Big Pharma a Swift and Devastating DEATHBLOW It Won’t Come Back From… “And Launch This Little Company on A 72-Hour, $8.98 Billion All-Out SPRINT” And there’s a deadline… today, in fact, when there will […]

[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]

Comments

  • Eisai is a partner with Biogen on aducanumab. ESALY is < $90 per share as opposed to BIIB at $285. ....

  • Another failure in Alzheimer's Disease trials... BIIB and Eisai discontinued their late Phase 3 trials because they were...

  • I think it must be Eisai Co Ltd OTC Pink - ESALY. Denali doesn't LL it would have the ability to market Tumor Paint wo...

  • well we already own Eisai, ESALY so we can wait this pitch out....

  • After Lashmet's last pitch, I bought Eisai (ESALY) thinking that it was sure to double. I have received a couple of div...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info